Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of NEVANAC 0.1% versus vehicle in preventing macular edema after cataract surgery in diabetic retinopathy
2009-010536-17Phase 2Terminated
- Sponsor
- ALCON RESEARCH, LTD.
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Irvine-Gass syndrome (IGS) and cystoid macular edema (CME) comparing NEVANAC 0.1% arm with Vehicle (placebo) arm (2 arms). Primary endpoint: Incidence of macular edema within 90 days after cataract surgery. Started Mar 2009; status: terminated.
02
Drugs
nepafenac
03
Conditions
Irvine-Gass syndrome (IGS)cystoid macular edema (CME)
Beyond the preview
Go deeper on 2009-010536-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010536-17.